<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PHENERGAN- promethazine hydrochloride injection </strong><br>West-ward Pharmaceutical Corp.<br></p></div>
<h1>PHENERGAN Injection (promethazine hydrochloride injection, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e538fe5a-389d-478e-b26e-d25e18c31a4b"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Warning">
<a name="LINK_ec5c0224-efea-45d8-aca2-5ea242db9692"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span> – Pediatrics</span></p>
<p><span class="Bold">PHENERGAN Injection should not be used in pediatric patients less than 2 years of age because of the potential for fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Postmarketing cases of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, including fatalities, have been reported with use of promethazine in pediatric patients less than 2 years of age. Caution should be exercised when administering PHENERGAN Injection to pediatric patients 2 years of age and older (see </span><a href="#LINK_707614dd-647d-4fcf-8bb4-11697a044b6f">WARNINGS - <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a><span class="Bold">).</span></p>
<p><span class="Bold">Severe Tissue Injury, Including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></span></p>
<p><span class="Bold">PHENERGAN Injection can cause severe chemical irritation and <span class="Underline">damage to tissues regardless of the route of administration</span>. Irritation and damage can result from perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, unintentional intra-arterial injection, and intraneuronal or perineuronal infiltration. Adverse reactions include burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, and <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>. In some cases, <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>, including fasciotomy, skin graft, and/or amputation have been required (see </span><a href="#LINK_104b719b-209f-4e98-bb5f-cb6ed165361b">WARNINGS - Severe Tissue Injury, Including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></a><span class="Bold">).</span></p>
<p><span class="Bold">Due to the risks of intravenous injection, the preferred route of administration of PHENERGAN Injection is deep intramuscular injection. Subcutaneous injection is contraindicated. See </span><a href="#LINK_fd9088e9-0e53-4141-97b9-cb79273302ad">DOSAGE AND ADMINISTRATION</a><span class="Bold"> for important notes on administration.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_7f42a990-76d3-4831-aeff-599d90ec95ed"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PHENERGAN Injection (promethazine hydrochloride injection, USP), is a sterile, pyrogen-free solution for deep intramuscular or intravenous administration. Promethazine hydrochloride (10<span class="Italics">H</span>-Phenothiazine-10-ethanamine,<span class="Italics">N,N,</span>α-trimethyl-, monohydrochloride, (±)-) is a racemic compound and has the following structural formula:</p>
<div class="Figure"><img alt="promethazine hydrochloride structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6f7e47cc-f823-4336-8107-f980e3049617&amp;name=phenergan-injection---portugal-ampul-1.jpg"></div>
<p>C<span class="Sub">17</span>H<span class="Sub">21</span>ClN<span class="Sub">2</span>S       MW 320.88</p>
<p>Each mL contains promethazine hydrochloride, either 25 mg or 50 mg, edetate disodium 0.1 mg, calcium chloride 0.04 mg, sodium metabisulfite 0.25 mg and phenol 5 mg in Water for Injection. pH 4.0 to 5.5; buffered with acetic acid-sodium acetate.</p>
<p>PHENERGAN Injection (promethazine hydrochloride injection, USP) is a clear, colorless solution. The product is light sensitive. It should be inspected before use and discarded if either color or particulate is observed.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_fe3d96d9-d332-4ea6-a4f9-5c309a81b2fa"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Promethazine hydrochloride is a phenothiazine derivative which
                            possesses antihistaminic, sedative, antimotion-sickness, antiemetic, and
                            anticholinergic effects. Promethazine is a competitive H<span class="Sub">1</span>
                            receptor antagonist, but does not block the release of histamine.
                            Structural differences from the neuroleptic phenothiazines result in its
                            relative lack (1<span class="Bold">/</span>10 that of
                            chlorpromazine) of dopamine antagonist properties. Clinical effects are
                            generally apparent within 5 minutes of an intravenous injection and
                            within 20 minutes of an intramuscular injection. Duration of action is
                            four to six hours, although effects may persist up to 12 hours.
                            Promethazine hydrochloride is metabolized in the liver, with the
                            sulfoxides of promethazine and N-desmethylpromethazine being the
                            predominant metabolites appearing in the urine. Following intravenous
                            administration in healthy volunteers, the plasma half-life for
                            promethazine has been reported to range from 9 to 16 hours. The mean
                            plasma half-life for promethazine after intramuscular administration in
                            healthy volunteers has been reported to be 9.8 ± 3.4 hours.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_74283475-6b85-457f-a4f2-120e3f71e9d5"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">PHENERGAN Injection is indicated for the following conditions:</p>
<ol class="Arabic">
<li>Amelioration of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to blood or plasma. 
</li>
<li>In <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. 
</li>
<li>For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. 
</li>
<li>For sedation and relief of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span> and to produce light sleep from which the patient can be easily aroused. 
</li>
<li>Active treatment of <span class="product-label-link" type="condition" conceptid="30284" conceptname="Motion sickness">motion sickness</span>. 
</li>
<li>Prevention and control of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with certain types of anesthesia and surgery. 
</li>
<li>As an adjunct to analgesics for the control of <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>. 
</li>
<li>Preoperative, postoperative, and obstetric (during labor) sedation. 
</li>
<li>Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_e6c852a5-99bd-4b1b-9814-7aab562c7d8b"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c8e6fdb6-22c7-4dab-a4e9-6cffdac39988"></a><a name="section-5.1"></a><p></p>
<h2>Children Less Than 2 Years of Age</h2>
<p class="First">PHENERGAN Injection is contraindicated for use in
                                    pediatric patients less than two years of age due to the risk of
                                    <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> <span class="Bold">(</span>see 
                                        <a href="#LINK_707614dd-647d-4fcf-8bb4-11697a044b6f">WARNINGS - <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a><span class="Bold">)</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f5b35410-71ee-42fa-b287-2407cb4fa7cb"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Comatose</span> State</h2>
<p class="First">PHENERGAN Injection is contraindicated in <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span>
                                    states.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ab1c4e10-0cb2-4195-bda2-8c9470e5a668"></a><a name="section-5.3"></a><p></p>
<h2>Intra-Arterial Injection</h2>
<p class="First">Under no circumstances should PHENERGAN Injection be
                                    given by intra-arterial injection due to the likelihood of
                                    severe <span class="product-label-link" type="condition" conceptid="4292397" conceptname="Arteriospasm">arteriospasm</span> and the possibility of resultant <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>
                                    (see <a href="#LINK_104b719b-209f-4e98-bb5f-cb6ed165361b">WARNINGS - Severe Tissue Injury, Including
                                        <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6d1a218c-6ac4-41f2-8623-bd779ded5e9a"></a><a name="section-5.4"></a><p></p>
<h2>Subcutaneous Injection</h2>
<p class="First">PHENERGAN Injection should not be given by the
                                    subcutaneous route because evidence of chemical irritation has
                                    been noted, and necrotic lesions have resulted following
                                    subcutaneous injection. The preferred parenteral route of
                                    administration is by deep intramuscular injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cb9b06a6-6d9a-41ba-b95d-b56f28f3d64f"></a><a name="section-5.5"></a><p></p>
<h2>Idiosyncratic Reaction or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">PHENERGAN Injection is contraindicated in patients who
                                    have demonstrated an idiosyncratic reaction or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>
                                    to promethazine or other phenothiazines.</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_533287f8-9334-40ef-8a47-ac73cfa568b9"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_707614dd-647d-4fcf-8bb4-11697a044b6f"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_65a17f51-f238-4c65-931a-0940877c5f7a"></a><a name="section-6.1.1"></a><p></p>
<h3>Pediatrics</h3>
<p class="First"><span class="Bold">PHENERGAN Injection should not
                                                be used in pediatric patients less than 2 years of
                                                age because of the potential for fatal respiratory
                                                <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Postmarketing cases of respiratory
                                                <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, including fatalities, have been reported
                                                with use of promethazine in pediatric patients less
                                                than 2 years of age. A wide range of weight-based
                                                doses of PHENERGAN Injection have resulted in
                                                <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in these patients.</span></p>
<p><span class="Bold">Caution should be exercised
                                                when administering PHENERGAN Injection to pediatric
                                                patients 2 years of age and older. It is recommended
                                                that the lowest effective dose of PHENERGAN
                                                Injection be used in pediatric patients 2 years of
                                                age and older. Avoid concomitant administration of
                                                other drugs with respiratory depressant effects
                                                because of an association with respiratory
                                                <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and sometimes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, in pediatric
                                                patients.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_936a9ccd-eea4-40cb-89ec-6189b01e16dc"></a><a name="section-6.1.2"></a><p></p>
<h3>Other</h3>
<p class="First">Because of the risk of potentially fatal
                                            <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, use of PHENERGAN Injection in
                                            patients with compromised respiratory function or
                                            patients at risk for <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> (e.g. <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>,
                                            <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>) should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_104b719b-209f-4e98-bb5f-cb6ed165361b"></a><a name="section-6.2"></a><p></p>
<h2>Severe Tissue Injury, Including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></h2>
<p class="First"><span class="Bold">PHENERGAN Injection can cause severe
                                        chemical irritation and <span class="Underline">damage to tissues regardless of the route of
                                            administration</span>. Irritation and damage can
                                        result from perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, unintentional
                                        intra-arterial injection, and intraneuronal or perineuronal
                                        infiltration. Adverse event reports include burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>,
                                        <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">sensory loss</span>, palsies, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, severe
                                        spasm of distal vessels, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, venous
                                        <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, and
                                        <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>. In some cases, <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>, including
                                        fasciotomy, skin graft, and/or amputation have been
                                        required. </span></p>
<p><span class="Bold">Because of the risks of intravenous
                                        injection, the preferred route of administration of
                                        PHENERGAN Injection is deep intramuscular injection (see </span><a href="#LINK_fd9088e9-0e53-4141-97b9-cb79273302ad">DOSAGE AND ADMINISTRATION</a><span class="Bold">). Subcutaneous injection is
                                        contraindicated. Due to the close proximity of arteries and
                                        veins in the areas most commonly used for intravenous
                                        injection, extreme care should be exercised to avoid
                                        perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> or unintentional intra-arterial
                                        injection as <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, severe chemical irritation, severe spasm
                                        of distal vessels, and resultant <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> requiring
                                        amputation are likely under such circumstances. <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">Aspiration</span>
                                        of dark blood does not preclude intra-arterial needle
                                        placement because blood is discolored upon contact with
                                        PHENERGAN Injection. Use of syringes with rigid plungers or
                                        of small-bore needles might obscure typical arterial
                                        backflow if this is relied upon alone.</span></p>
<p><span class="Bold">In the event that a patient complains
                                        of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> during intravenous injection of Phenergan Injection,
                                        the injection should be stopped immediately to evaluate for
                                        possible arterial injection or perivascular
                                        <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.</span></p>
<p><span class="Bold">There is no proven successful
                                        management of unintentional intra-arterial injection or
                                        perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> after it occurs. Sympathetic
                                        block and heparinization have been employed during the acute
                                        management of unintentional intra-arterial injection,
                                        because of the results of animal experiments with other
                                        known arteriolar irritants.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_467fe4a0-d0f5-4588-b20f-edeac3bdc1fa"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span></h2>
<p class="First">PHENERGAN Injection may impair the mental and/or physical
                                    abilities required for the performance of potentially hazardous
                                    tasks, such as driving a vehicle or operating machinery. The
                                    impairment may be amplified by concomitant use of other
                                    central-nervous-system depressants such as alcohol,
                                    sedative/hypnotics (including barbiturates), general
                                    anesthetics, narcotics, narcotic analgesics, tricyclic
                                    antidepressants, and tranquilizers; therefore such agents should
                                    either be eliminated or given in reduced dosage in the presence
                                    of promethazine hydrochloride (see <a href="#LINK_0d22040e-0770-42e6-b48c-dca136417d33">PRECAUTIONS - Information for Patients</a> and
                                        <a href="#LINK_f537a07b-9ec2-44a5-b88b-5219b425f32b">Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ee4e6600-2c00-4229-8427-090a011bccea"></a><a name="section-6.4"></a><p></p>
<h2>Lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Threshold</h2>
<p class="First">PHENERGAN Injection may lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold and
                                    should be used with caution in persons with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders or
                                    in persons who are using concomitant medications, such as
                                    narcotics or local anesthetics, which may also affect <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>
                                    threshold.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d80a5189-6216-49ef-9aa1-b5bcbefdac1a"></a><a name="section-6.5"></a><p></p>
<h2>Bone-<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Marrow Depression</span></h2>
<p class="First">PHENERGAN Injection should be used with caution in
                                    patients with bone-<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow depression</span>. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> and
                                    <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported, usually when promethazine
                                    hydrochloride has been used in association with other known
                                    marrow-toxic agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7b191fb0-9915-48c7-84c1-f374f4ef7ec6"></a><a name="section-6.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></h2>
<p class="First">A potentially fatal symptom complex sometimes referred to
                                    as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in
                                    association with promethazine hydrochloride alone or in
                                    combination with antipsychotic drugs. Clinical manifestations of
                                    NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status and
                                    evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood
                                    pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and cardiac
                                    <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span>).</p>
<p>The diagnostic evaluation of patients with this syndrome
                                    is complicated. In arriving at a diagnosis, it is important to
                                    identify cases where the clinical presentation includes both
                                    serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>,
                                    etc.) and untreated or inadequately treated extrapyramidal signs
                                    and symptoms (EPS). Other important considerations in the
                                    differential diagnosis include central anticholinergic toxicity,
                                    <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span> and primary central nervous system (CNS)
                                    pathology.</p>
<p>The management of NMS should include 1) immediate
                                    discontinuation of promethazine hydrochloride, antipsychotic
                                    drugs, if any, and other drugs not essential to concurrent
                                    therapy, 2) intensive symptomatic treatment and medical
                                    monitoring, and 3) treatment of any concomitant serious medical
                                    problems for which specific treatments are available. There is
                                    no general agreement about specific pharmacological treatment
                                    regimens for uncomplicated NMS.</p>
<p>Since recurrences of NMS have been reported with
                                    phenothiazines, the reintroduction of promethazine hydrochloride
                                    should be carefully considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cf755f60-1394-4569-aae8-731d237711a6"></a><a name="section-6.7"></a><p></p>
<h2>Sulfite Sensitivity</h2>
<p class="First">PHENERGAN Injection contains sodium metabisulfite, a
                                    sulfite that may cause allergic-type reactions, including
                                    anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>
                                    episodes, in certain susceptible people. The overall prevalence
                                    of sulfite sensitivity in the general population is unknown and
                                    probably low. Sulfite sensitivity is seen more frequently in
                                    <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_df1deb38-1716-48de-92ba-1af188839221"></a><a name="section-6.8"></a><p></p>
<h2>Visual Inspection</h2>
<p class="First">This product is light sensitive and should be inspected
                                    before use and discarded if either color or particulate is
                                    observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f7ec336b-87b0-4331-9e30-98c168bf5a3a"></a><a name="section-6.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span></h2>
<p class="First">Administration of promethazine has been associated with
                                    reported <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_478207b4-efc0-434f-a9df-710fa63b4299"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_beb607b0-7642-46ff-9773-9f99266549d0"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Drugs having anticholinergic properties should be used
                                    with caution in patients with narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, prostatic
                                    <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>, stenosing <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, pyloroduodenal obstruction,
                                    and bladder-neck obstruction.</p>
<p>PHENERGAN Injection should be used cautiously in persons
                                    with cardiovascular disease or impairment of liver
                                    function.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_0d22040e-0770-42e6-b48c-dca136417d33"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be advised of the risk of respiratory
                                    <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, including potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>
                                    in children less than 2 years of age (see <a href="#LINK_707614dd-647d-4fcf-8bb4-11697a044b6f">WARNINGS - <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a>).</p>
<p>Patients should be advised of the risk of severe tissue
                                    injury, including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> (see <a href="#LINK_104b719b-209f-4e98-bb5f-cb6ed165361b">WARNINGS - Severe Tissue Injury, Including
                                        <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></a>). Patients should be advised to
                                    immediately report persistent or worsening <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or burning at
                                    the injection site.</p>
<p>PHENERGAN Injection may cause marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or impair
                                    the mental or physical abilities required for the performance of
                                    potentially hazardous tasks, such as driving a vehicle or
                                    operating machinery. Pediatric patients should be supervised to
                                    avoid potential harm in bike riding or in other hazardous
                                    activities. The concomitant use of alcohol, sedative/hypnotics
                                    (including barbiturates), general anesthetics, narcotics,
                                    narcotic analgesics, tricyclic antidepressants, and
                                    tranquilizers may enhance impairment (see <a href="#LINK_467fe4a0-d0f5-4588-b20f-edeac3bdc1fa">WARNINGS - <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span></a> and <a href="#LINK_f537a07b-9ec2-44a5-b88b-5219b425f32b">PRECAUTIONS - Drug Interactions</a>).</p>
<p>Patients should be advised to report any involuntary
                                    muscle movements (see  <a href="#LINK_c1e26015-efc2-4027-91c1-7825795b522b">ADVERSE REACTIONS - Paradoxical
                                    Reactions</a>).</p>
<p>Patients should be advised to avoid prolonged exposure to
                                    the sun (see <a href="#LINK_2448498e-2061-41a9-b760-b1e96de0e0e5">ADVERSE REACTIONS - Dermatologic</a>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_f537a07b-9ec2-44a5-b88b-5219b425f32b"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f768c6ee-2e7d-4a19-a229-d920a2fabef5"></a><a name="section-7.3.1"></a><p></p>
<h3>CNS Depressants</h3>
<p class="First">PHENERGAN Injection may increase, prolong, or
                                            intensify the sedative action of central-nervous-system
                                            depressants, such as alcohol, sedative/hypnotics
                                            (including barbiturates), general anesthetics,
                                            narcotics, narcotic analgesics, tricyclic
                                            antidepressants, and tranquilizers; therefore, such
                                            agents should be avoided or administered in reduced
                                            dosage to patients receiving promethazine hydrochloride.
                                            When given concomitantly with PHENERGAN Injection, the
                                            dose of barbiturates should be reduced by at least
                                            one-half, and the dose of narcotics should be reduced by
                                            one-quarter to one-half. Dosage must be individualized.
                                            Excessive amounts of PHENERGAN Injection relative to a
                                            narcotic may lead to <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and motor
                                            <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> in the patient with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; these symptoms
                                            usually disappear with adequate control of the
                                            <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9052de28-14a0-411f-af9e-d47f40024f7a"></a><a name="section-7.3.2"></a><p></p>
<h3>Epinephrine</h3>
<p class="First">Because of the potential for promethazine
                                            hydrochloride to reverse epinephrine’s vasopressor
                                            effect, epinephrine should NOT be used to treat
                                            <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> associated with PHENERGAN Injection
                                            <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_756192d1-a5f2-460e-b8a3-0eb48bf8de55"></a><a name="section-7.3.3"></a><p></p>
<h3>Anticholinergics</h3>
<p class="First">Concomitant use of other agents with
                                            anticholinergic properties should be undertaken with
                                            caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a5a2811a-43f7-4388-a1ef-88d9bac22541"></a><a name="section-7.3.4"></a><p></p>
<h3>Monoamine Oxidase (MAO) Inhibitors</h3>
<p class="First">Drug interactions, including an increased
                                            incidence of extrapyramidal effects, have been reported
                                            when some MAO Inhibitors and phenothiazines are used
                                            concomitantly. This possibility should be considered
                                            with PHENERGAN Injection.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_7e4b86c5-98fe-4f24-8650-7f7d291f5e5e"></a><a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">The following laboratory tests may be affected in
                                    patients who are receiving therapy with PHENERGAN
                                    Injection:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c3afa993-57f1-4629-805f-be03bb759be5"></a><a name="section-7.4.1"></a><p></p>
<h3>Pregnancy Tests</h3>
<p class="First">Diagnostic pregnancy tests based on immunological
                                            reactions between HCG and anti-HCG may result in
                                            false-negative or false-positive
                                            interpretations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6eb1e305-6da5-44c7-b235-124e98d7b762"></a><a name="section-7.4.2"></a><p></p>
<h3>Glucose Tolerance Test</h3>
<p class="First">An increase in blood glucose has been reported in
                                            patients receiving promethazine
                                            hydrochloride.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_12eb6c2d-7209-4a9e-8a77-c9af37afd7cb"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis and Impairment of Fertility</h2>
<p class="First">Long-term animal studies have not been performed to
                                    assess the carcinogenic potential of PHENERGAN Injection, nor
                                    are there other animal or human data concerning carcinogenicity,
                                    mutagenicity, or impairment of fertility. PHENERGAN Injection
                                    was nonmutagenic in the <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> test system of Ames.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_58dfceac-138c-4cde-bd97-68193e89c8d7"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_abee017c-c8af-4534-90f9-3df6d1a524fa"></a><a name="section-7.6.1"></a><p></p>
<h3>Teratogenic Effects—Pregnancy Category C</h3>
<p class="First">Teratogenic effects have not been demonstrated in
                                            rat-feeding studies at doses of 6.25 and 12.5 mg/kg
                                            (approximately 2.1 and 4.2 times the maximum recommended
                                            human daily dose) of PHENERGAN Injection. Daily doses of
                                            25 mg/kg intraperitoneally have been found to produce
                                            fetal mortality in rats.</p>
<p>There are no adequate and well-controlled studies
                                            of PHENERGAN Injection in pregnant women. Because animal
                                            reproduction studies are not always predictive of human
                                            response, PHENERGAN Injection should be used during
                                            pregnancy only if the potential benefit justifies the
                                            potential risk to the fetus.</p>
<p>Adequate studies to determine the action of the
                                            drug on parturition, lactation and development of the
                                            animal neonate have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_c29c2435-ea61-404b-a631-a2704bf4f314"></a><a name="section-7.6.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">PHENERGAN Injection administered to a pregnant
                                            woman within two weeks of delivery may inhibit platelet
                                            aggregation in the newborn.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_4e91e997-a317-461d-a994-f63e1107e308"></a><a name="section-7.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">PHENERGAN Injection may be used alone or as an adjunct to
                                    narcotic analgesics during labor (see <a href="#LINK_fd9088e9-0e53-4141-97b9-cb79273302ad">DOSAGE AND ADMINISTRATION</a>). Limited data suggest
                                    that use of PHENERGAN Injection during labor and delivery does
                                    not have an appreciable effect on the duration of labor or
                                    delivery and does not increase the risk of need for intervention
                                    in the newborn. The effect on later growth and development of
                                    the newborn is unknown. (See also <a href="#LINK_c29c2435-ea61-404b-a631-a2704bf4f314">Pregnancy - Nonteratogenic Effects</a>.)</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_794cb7c6-e74d-4f37-9307-ade2b0f38643"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether PHENERGAN Injection is excreted
                                    in human milk. Because many drugs are excreted in human milk,
                                    and because of the potential for serious adverse reactions in
                                    nursing infants from PHENERGAN Injection, a decision should be
                                    made whether to discontinue nursing or to discontinue the drug,
                                    taking into account the importance of the drug to the
                                    mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_aa0e624b-76b1-4f14-8ed8-69dd93851eb3"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">PHENERGAN Injection is contraindicated for use in
                                    pediatric patients less than 2 years of age, because of the
                                    potential for fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. PHENERGAN Injection
                                    should be used with caution in pediatric patients 2 years of age
                                    and older (see <a href="#LINK_707614dd-647d-4fcf-8bb4-11697a044b6f">WARNINGS - <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a>).</p>
<p>Antiemetics are not recommended for treatment of
                                    uncomplicated <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in pediatric patients, and their use
                                    should be limited to prolonged <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> of known etiology. The
                                    <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> which can occur secondary to PHENERGAN
                                    Injection administration may be <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> with the CNS signs of
                                    undiagnosed primary disease, e.g. <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> or Reye's
                                    syndrome. The use of PHENERGAN Injection should be avoided in
                                    pediatric patients whose signs and symptoms may suggest Reye's
                                    syndrome or other <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic diseases</span>.</p>
<p>Excessively large dosages of antihistamines, including
                                    PHENERGAN Injection, in pediatric patients may cause sudden
                                    <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (see <a href="#LINK_72b70229-d841-4736-9fac-fa3ef3dea2a7">OVERDOSAGE</a>). <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>
                                    and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> have occurred with therapeutic doses and
                                    <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of PHENERGAN Injection in pediatric patients. In
                                    pediatric patients who are acutely ill associated with
                                    <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, there is an increased susceptibility to <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonias</span>
                                    with the use of PHENERGAN Injection.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_87420b2c-07e2-4dcf-a0e2-8dd7d0a60e89"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric Use (patients approximately 60 years or older)</h2>
<p class="First">Since therapeutic requirements for sedative drugs tend to
                                    be less in geriatric patients, the dosage should be reduced for
                                    these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_53dcdc11-2f08-4bcc-8c63-d59ed1079902"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_49c38216-cf6a-47d3-98d2-65c717a868ba"></a><a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First">PHENERGAN Injection is contraindicated in pediatric
                                    patients less than 2 years of age, because of the potential for
                                    fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. PHENERGAN Injection should be used
                                    with caution in pediatric patients 2 years of age and older (see
                                        <a href="#LINK_707614dd-647d-4fcf-8bb4-11697a044b6f">WARNINGS - <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_89204a02-ea22-4648-8b82-66e72e1ee26d"></a><a name="section-8.2"></a><p></p>
<h2>Severe Tissue Injury, Including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></h2>
<p class="First">PHENERGAN Injection can cause severe chemical irritation
                                    and <span class="Underline">damage to tissues regardless
                                        of the route of administration</span>. Irritation and
                                    damage can result from perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, unintentional
                                    intra-arterial injection, and intraneuronal or perineuronal
                                    infiltration. Adverse reactions include burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>,
                                    <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">sensory loss</span>, palsies, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, severe spasm of
                                    distal vessels, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>,
                                    <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, and <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>. In some cases,
                                    <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>, including fasciotomy, skin graft, and/or
                                    amputation have been required (see <a href="#LINK_104b719b-209f-4e98-bb5f-cb6ed165361b">WARNINGS - Severe Tissue Injury, Including
                                        <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></a>; and <a href="#LINK_fd9088e9-0e53-4141-97b9-cb79273302ad">DOSAGE AND
                                        ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5a1a7964-03b3-42c1-9355-9dc5acf58737"></a><a name="section-8.3"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> is the most prominent CNS effect of this drug.
                                    Sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>,
                                    <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> such as oculogyric
                                    crisis, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, and tongue protrusion; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>,
                                    <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>,
                                    <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, excitation,
                                    <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonic</span>-like states, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> have also been
                                    reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bb992619-5824-4252-b40c-f35c4768c192"></a><a name="section-8.4"></a><p></p>
<h2>Cardiovascular</h2>
<p class="First">Increased or decreased blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>,
                                    <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, faintness.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2448498e-2061-41a9-b760-b1e96de0e0e5"></a><a name="section-8.5"></a><p></p>
<h2>Dermatologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3a1400e8-39ee-40e2-b843-f703cb5fc004"></a><a name="section-8.6"></a><p></p>
<h2>Hematologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>,
                                    <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b4901f78-b34b-4bb9-9282-512a5a2bc812"></a><a name="section-8.7"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d0e6854b-306e-4231-b0e8-63dc9ae64e62"></a><a name="section-8.8"></a><p></p>
<h2>Respiratory</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>
                                    (potentially fatal) and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> (potentially fatal). (See
                                        <a href="#LINK_707614dd-647d-4fcf-8bb4-11697a044b6f">WARNINGS - <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_99bf63f2-03bd-413d-996c-f6ce6d238317"></a><a name="section-8.9"></a><p></p>
<h2>Other</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioneurotic edema</span>. <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>
                                    (potentially fatal) has also been reported. (See <a href="#LINK_7b191fb0-9915-48c7-84c1-f374f4ef7ec6">WARNINGS - <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></a>.)
                                </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c1e26015-efc2-4027-91c1-7825795b522b"></a><a name="section-8.10"></a><p></p>
<h2>Paradoxical Reactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Hyperexcitability</span> and abnormal movements have been
                                    reported in patients following a single administration of
                                    PHENERGAN Injection. Consideration should be given to the
                                    discontinuation of PHENERGAN Injection and to the use of other
                                    drugs if these reactions occur. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>,
                                    <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> behavior have also been
                                    reported in some of these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_72b70229-d841-4736-9fac-fa3ef3dea2a7"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Signs and symptoms of overdosage range from mild <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of
                            the central nervous system and cardiovascular system to profound
                            <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>.
                            Other reported reactions include <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>,
                            <span class="product-label-link" type="condition" conceptid="4259277" conceptname="Athetosis">athetosis</span>, and extensor-plantar reflexes (Babinski reflex).</p>
<p>Stimulation may be evident, especially in pediatric patients and
                            geriatric patients. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> may rarely occur. A paradoxical-type
                            reaction has been reported in pediatric patients receiving single doses
                            of 75 mg to 125 mg orally, characterized by <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">hyperexcitability</span> and
                            <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>.</p>
<p>Atropine-like signs and symptoms-<span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>; fixed, dilated
                            pupils; <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; etc., as well as <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, may
                            occur.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_89db434d-53a7-446f-9f3d-1b5cee604a1a"></a><a name="section-9.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">Treatment of overdosage is essentially symptomatic and
                                    supportive. Only in cases of extreme overdosage or individual
                                    sensitivity do vital signs, including respiration, pulse, blood
                                    pressure, temperature, and EKG, need to be monitored. Attention
                                    should be given to the reestablishment of adequate respiratory
                                    exchange through provision of a patent airway and institution of
                                    assisted or controlled ventilation. Diazepam may be used to
                                    control <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span> and electrolyte losses should be
                                    corrected. Note that any depressant effects of PHENERGAN
                                    Injection are not reversed by naloxone.</p>
<p>Avoid analeptics, which may cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. The
                                    treatment of choice for resulting <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is administration
                                    of intravenous fluids, accompanied by repositioning if
                                    indicated. In the event that vasopressors are considered for the
                                    management of severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> which does not respond to
                                    intravenous fluids and repositioning, the administration of
                                    norepinephrine or phenylephrine should be considered.
                                    EPINEPHRINE SHOULD NOT BE USED, since its use in a patient with
                                    partial adrenergic blockade may further lower the blood
                                    pressure. Extrapyramidal reactions may be treated with
                                    anticholinergic antiparkinson agents, diphenhydramine, or
                                    barbiturates. Oxygen may also be administered. Limited
                                    experience with dialysis indicates that it is not
                                    helpful.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_fd9088e9-0e53-4141-97b9-cb79273302ad"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_af837d49-a656-4dc7-8c72-4d3385b494b9"></a><a name="section-10.1"></a><p></p>
<h2>Important Notes on Administration</h2>
<p class="First">PHENERGAN Injection can cause severe chemical irritation
                                    and <span class="Bold">damage to tissues regardless of
                                        the route of administration</span>. Irritation and damage
                                    can result from perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, unintentional
                                    intra-arterial injection, and intraneuronal or perineuronal
                                    infiltration (see <a href="#LINK_104b719b-209f-4e98-bb5f-cb6ed165361b">WARNINGS - Severe Tissue Injury, Including
                                        <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></a>).</p>
<ul class="Disk">
<li><span class="Bold">The preferred parenteral route of
                                            administration for PHENERGAN Injection is by deep
                                            intramuscular injection.</span></li>
<li>Under no circumstances should PHENERGAN Injection be given
                                        by intra-arterial injection due to the likelihood of severe
                                        <span class="product-label-link" type="condition" conceptid="4292397" conceptname="Arteriospasm">arteriospasm</span> and the possibility of resultant <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> (see
                                            <a href="#LINK_104b719b-209f-4e98-bb5f-cb6ed165361b">WARNINGS - Severe Tissue Injury, Including
                                            <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></a>).</li>
<li>Subcutaneous injection is contraindicated as it may result
                                        in tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>.</li>
<li>
<span class="Bold">When administered intravenously,
                                            PHENERGAN Injection should be given in a concentration
                                            no greater than 25 mg per mL and at a rate not to exceed
                                            25 mg per minute.</span> It is preferable to inject
                                        through the tubing of an intravenous infusion set that is
                                        known to be functioning satisfactorily.</li>
<li>In the event that a patient complains of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> during
                                        intravenous injection of PHENERGAN Injection, the injection
                                        should be stopped immediately to evaluate for possible
                                        arterial injection or perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.</li>
</ul>
<p>Parenteral drug products should be inspected visually for
                                    particulate matter and discoloration prior to administration,
                                    whenever solution and container permit.</p>
<p>Do not use PHENERGAN Injection if solution has developed
                                    color or contains precipitate.</p>
<p>To avoid the possibility of physical and/or chemical
                                    incompatibility, consult specialized literature before diluting
                                    with any injectable solution or combining with any other
                                    medication. Do not use if there is a precipitate or any sign of
                                    incompatibility.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e4fbc92a-552e-4854-ad89-2b804b3cdeab"></a><a name="section-10.2"></a><p></p>
<h2>Allergic Conditions</h2>
<p class="First">The average adult dose is 25 mg. This dose may be
                                    repeated within two hours if necessary, but continued therapy,
                                    if indicated, should be via the oral route as soon as existing
                                    circumstances permit. After initiation of treatment, dosage
                                    should be adjusted to the smallest amount adequate to relieve
                                    symptoms. The average adult dose for amelioration of allergic
                                    reactions to blood or plasma is 25 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d5b75972-7e84-4cc7-aa76-d19585150651"></a><a name="section-10.3"></a><p></p>
<h2>Sedation</h2>
<p class="First">In hospitalized adult patients, nighttime sedation may be
                                    achieved by a dose of 25 to 50 mg of PHENERGAN
                                    Injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_48c9bc89-7e9d-4761-8136-fed590180d08"></a><a name="section-10.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></h2>
<p class="First">For control of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, the usual adult dose
                                    is 12.5 to 25 mg, not to be repeated more frequently than every
                                    four hours. When used for control of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and
                                    <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, the dosage of analgesics and barbiturates should be
                                    reduced accordingly (see <a href="#LINK_f537a07b-9ec2-44a5-b88b-5219b425f32b">PRECAUTIONS – Drug Interactions</a>).</p>
<p>Antiemetics should not be used in <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> of unknown
                                    etiology in children and adolescents (see <a href="#LINK_aa0e624b-76b1-4f14-8ed8-69dd93851eb3">PRECAUTIONS – Pediatric Use</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9d9d0f38-be16-409c-a4c3-f8a702a5e04d"></a><a name="section-10.5"></a><p></p>
<h2>Preoperative and Postoperative Use</h2>
<p class="First">As an adjunct to preoperative or postoperative
                                    medication, 25 to 50 mg of PHENERGAN Injection in adults may be
                                    combined with appropriately reduced doses of analgesics and
                                    atropine-like drugs as desired. Dosage of concomitant analgesic
                                    or hypnotic medication should be reduced accordingly (see
                                        <a href="#LINK_f537a07b-9ec2-44a5-b88b-5219b425f32b">PRECAUTIONS – Drug Interactions</a>).</p>
<p>PHENERGAN is contraindicated for use in pediatric
                                    patients less than two years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5b4cd20b-d5c3-4d76-8d59-ff274a37299c"></a><a name="section-10.6"></a><p></p>
<h2>Obstetrics</h2>
<p class="First">PHENERGAN Injection in doses of 50 mg will provide
                                    sedation and relieve <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span> in the early stages of labor.
                                    When labor is definitely established, 25 to 75 mg (average dose,
                                    50 mg) PHENERGAN Injection may be given with an appropriately
                                    reduced dose of any desired narcotic (see <a href="#LINK_f537a07b-9ec2-44a5-b88b-5219b425f32b">PRECAUTIONS – Drug Interactions</a>). If necessary,
                                    PHENERGAN Injection with a reduced dose of analgesic may be
                                    repeated once or twice at four-hour intervals in the course of a
                                    normal labor. A maximum total dose of 100 mg of PHENERGAN
                                    Injection may be administered during a 24-hour period to
                                    patients in labor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_179d1984-67cd-4ef1-8d9e-90235653ba2b"></a><a name="section-10.7"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First"><span class="Bold">PHENERGAN Injection is contraindicated
                                        for use in pediatric patients less than 2 years of age (see </span><a href="#LINK_707614dd-647d-4fcf-8bb4-11697a044b6f">WARNINGS – <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a><span class="Bold">). </span><span class="Bold">Caution should be exercised when
                                        administering promethazine hydrochloride to pediatric
                                        patients 2 years of age or older. It is recommended that the
                                        lowest effective dose of promethazine hydrochloride be used
                                        in pediatric patients 2 years of age and older and
                                        concomitant administration of other drugs with respiratory
                                        depressant effects be avoided (see </span><a href="#LINK_707614dd-647d-4fcf-8bb4-11697a044b6f">WARNINGS – <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a><span class="Bold">).</span></p>
<p>In pediatric patients 2 years of age and older, the
                                    dosage should not exceed half that of the suggested adult dose.
                                    As an adjunct to premedication, the suggested dose is 1.1 mg per
                                    kg of body weight in combination with an appropriately reduced
                                    dose of narcotic or barbiturate and the appropriate dose of an
                                    atropine-like drug (see 
                                        <a href="#LINK_f537a07b-9ec2-44a5-b88b-5219b425f32b">PRECAUTIONS – Drug Interactions</a>). Antiemetics should not be used in <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> of
                                    unknown etiology in pediatric patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_b9f7450c-3296-4677-a9ab-65c41deefe22"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PHENERGAN Injection (promethazine hydrochloride injection, USP) is available as follows:</p>
<p>25 mg/mL     1 mL ampuls packaged in 25s (NDC 0641-6082-25)</p>
<p>50 mg/mL     1 mL ampuls packaged in 25s (NDC 0641-6083-25)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_42da3abe-be1b-4f6a-8f6f-5c5b3f494996"></a><a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First"><span class="Bold">Store at 20</span><span class="Bold">°-25</span><span class="Bold">°C (68</span><span class="Bold">°-77</span><span class="Bold">°F) [See USP Controlled Room Temperature].</span></p>
<p><span class="Bold">Protect from light. Keep covered in carton until time of use.</span></p>
<p><span class="Bold">Do not use if solution has developed color or contains a precipitate.</span></p>
<p>To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceutical Corp. at<br>1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</p>
<p>For Product Inquiry call 1-877-845-0689.</p>
<p>Phenergan is a registered trademark of Wyeth and is used under license.</p>
<p><span class="Bold">Manufactured by: </span>HIKMA FARMACÊUTICA (PORTUGAL), S.A.<br>Estrada do Rio da Mό, 8, 8A e 8B – Fervença – 2705-906 Terrugem SNT, PORTUGAL</p>
<p><span class="Bold">Distributed by:</span></p>
<div class="Figure"><img alt="West-Ward Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6f7e47cc-f823-4336-8107-f980e3049617&amp;name=phenergan-injection---portugal-ampul-2.jpg"></div>
<p><span class="Bold">WEST-WARD<br></span>PHARMACEUTICALS<br>Eatontown, NJ 07724 USA</p>
<p>Revised January 2012</p>
<p>462-639-00<br>PIN294-PHE/1                                                                                                                                                      </p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_ffc4a49c-2f93-43da-9048-777e9cf2c819"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First">Phenergan Injection (Promethazine HCI Inj., USP)<br>25 mg/mL 1 mL Ampul<br>NDC 0641-6082-01</p>
<div class="Figure">
<img alt="Phenergan Injection (Promethazine HCI Inj., USP) 25 mg/mL 1 mL Ampul" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6f7e47cc-f823-4336-8107-f980e3049617&amp;name=phenergan-injection---portugal-ampul-3.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_c198b40f-6ec7-4e82-bb95-7d0a141616cb"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First">Phenergan Injection (Promethazine HCI Inj., USP)<br>50 mg/mL 1 mL Ampul<br>NDC 0641-6083-01</p>
<div class="Figure">
<img alt="Phenergan Injection (Promethazine HCI Inj., USP) 50 mg/mL 1 mL Ampul" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6f7e47cc-f823-4336-8107-f980e3049617&amp;name=phenergan-injection---portugal-ampul-4.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PHENERGAN 		
					</strong><br><span class="contentTableReg">promethazine hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0641-6082</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROMETHAZINE HYDROCHLORIDE</strong> (PROMETHAZINE) </td>
<td class="formItem">PROMETHAZINE HYDROCHLORIDE</td>
<td class="formItem">25 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem">0.04 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem">0.25 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-6082-25</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-6082-01</td>
<td class="formItem">1 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA083312</td>
<td class="formItem">09/19/1973</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PHENERGAN 		
					</strong><br><span class="contentTableReg">promethazine hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0641-6083</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROMETHAZINE HYDROCHLORIDE</strong> (PROMETHAZINE) </td>
<td class="formItem">PROMETHAZINE HYDROCHLORIDE</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem">0.04 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem">0.25 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-6083-25</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-6083-01</td>
<td class="formItem">1 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA083312</td>
<td class="formItem">09/19/1973</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>West-ward Pharmaceutical Corp.
							(946499746)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Hikma Farmaceutica</td>
<td class="formItem"></td>
<td class="formItem">452742943</td>
<td class="formItem">ANALYSIS(0641-6082, 0641-6083), LABEL(0641-6082, 0641-6083), MANUFACTURE(0641-6082, 0641-6083), PACK(0641-6082, 0641-6083)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1cee9794-5b56-4d41-a27e-86ba9cbf831d</div>
<div>Set id: 6f7e47cc-f823-4336-8107-f980e3049617</div>
<div>Version: 2</div>
<div>Effective Time: 20120611</div>
</div>
</div> <div class="DistributorName">West-ward Pharmaceutical Corp.</div></p>
</body></html>
